Larian Studios head of design Nick Pechenin stepped in to answer a question about Divinity's loot system, explaining that the ...
Data suggest that when pharmacological Zn levels used, average daily gain and average daily feed intake can be improved with ...
Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of ...
MRM Health receives US FDA IND clearance to initiate phase 2b trial of MH002 in mild-to-moderate ulcerative colitis: Ghent, Belgium Saturday, January 10, 2026, 16:00 Hrs [IST] MRM ...
(n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points ...
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss ...
On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late ...
Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...
To make it easier for children with asthma to receive care at school, a new study will assess the impact of making the ...
Artificial sweeteners have long been cast as either miracle weight-loss allies or metabolic saboteurs — but the science is ...
BD (NYSE: BDX) today announced the first Phasix hernia mesh laparotomy reinforcement case performed in Greece.
Dr. Raza Bokhari, Executive Chairman & CEO of Medicus will deliver a company presentation as Medicus enters 2026 with multiple Phase 2 Catalysts across clinical, regulatory, and pipeline expansion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback